A Multicenter, Non-randomized, Open-label Phase 1b Study to Determine the Maximum Tolerated and Recommended Phase 2 Dose of the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients With Advanced Solid Tumors
What is the purpose of this trial?
The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with BAY1895344 in combination with pembrolizumab. In addition researchers want to find for patients the optimal dose of BAY1895344 in combination with pembrolizumab, how the drug is tolerated and the way the body absorbs, distributes and discharges the drug. The study medication, BAY1895344, works by blocking a substance (ATR Kinase) which is produced by the body and is important for the growth of tumor cells. Pembrolizumab is an immunologic checkpoint blocker that promotes an immune response against the tumor.
- Trial withBayer Healthcare Pharmaceuticals, Inc.
- Start Date04/19/2021
- End Date04/15/2024
- Last Updated07/15/2021
- Study HIC#2000028686